Accelerate Diagnostics (NASDAQ:AXDX) Upgraded at StockNews.com

StockNews.com upgraded shares of Accelerate Diagnostics (NASDAQ:AXDX) from a sell rating to a hold rating in a research note published on Thursday.

Accelerate Diagnostics Stock Down 1.1 %

Shares of NASDAQ AXDX opened at $1.85 on Thursday. The firm has a market capitalization of $46.33 million, a P/E ratio of -0.65 and a beta of 0.59. The stock’s 50-day simple moving average is $1.78 and its two-hundred day simple moving average is $1.47. Accelerate Diagnostics has a twelve month low of $0.73 and a twelve month high of $5.78.

Institutional Investors Weigh In On Accelerate Diagnostics

An institutional investor recently raised its position in Accelerate Diagnostics stock. Griffin Asset Management Inc. increased its holdings in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) by 1.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,380,654 shares of the medical research company’s stock after purchasing an additional 26,400 shares during the quarter. Griffin Asset Management Inc. owned 6.26% of Accelerate Diagnostics worth $1,615,000 as of its most recent filing with the Securities & Exchange Commission. 17.14% of the stock is owned by hedge funds and other institutional investors.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.